ICM
RGNX icon

Invenomic Capital Management’s Regenxbio RGNX Stock Holding History

Invenomic Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-426,904
Closed -$4.12M – 165
2025
Q3 		$4.12M Buy
+426,904
New +$3.78M 0.2% 113

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Invenomic Capital Management's RGNX Position: Q4 2025 in Review

Invenomic Capital Management sold out of Regenxbio (RGNX) in Q4 2025, closing a stake of 426,904 shares — an estimated $4.12M sold.

Invenomic Capital Management first reported a position in RGNX in Q3 2025 and held it in 1 quarter. The position peaked at $4.12M in Q3 2025. 174 funds tracked by Wall St. Rank hold RGNX as of Q4 2025.

  • Invenomic Capital Management reported no remaining Regenxbio position as of Q4 2025 after selling out during the quarter.
  • Invenomic Capital Management sold 426,904 Regenxbio shares in Q4 2025, an estimated $4.12M.
  • Invenomic Capital Management first reported a position in Regenxbio in Q3 2025 and held it in 1 quarter.
  • Invenomic Capital Management's Regenxbio position peaked at $4.12M in Q3 2025.
  • 174 funds tracked by Wall St. Rank held Regenxbio as of Q4 2025.

Based on Invenomic Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.